Guangzhou Innogen Pharmaceutical Group Co., Ltd.
廣州銀諾醫藥集團股份有限公司
(A joint stock company established in the People's Republic of China with limited liability)
(Stock Code: 2591)

INSIDE INFORMATION PROPOSED IMPLEMENTATION OF THE H SHARE FULL CIRCULATION

This announcement is made by Guangzhou Innogen Pharmaceutical Group Co., Ltd. (the "**Company**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities (the "**Listing Rules"**) on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

References are made to (i) the Guidelines for the Application by H-share Companies for "Full Circulation" of Unlisted Shares (《H股公司境內未上市股份申請「全流通」業務指引》) promulgated by the China Securities Regulatory Commission (the "**CSRC**") on 14 November 2019 and further amended on 10 August 2023 (the "**Guidelines**"); and (ii) the Trial Administrative Measures of Overseas Securities Offering and Listing by Domestic Companies (《境內企業境外發行證券和上市管理試行辦法》) promulgated by the CSRC on 17 February 2023.

In light of the Guidelines, the board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that on 17 March 2026, the Company submitted the filing application to the CSRC in respect of the proposed conversion of all of its domestic unlisted shares into H shares of the Company (the "**H Shares**"). Upon obtaining all relevant approvals and/or filings (including the filing notice from the CSRC and the approval of the Stock Exchange) and having complied with all applicable laws, regulations and rules, such domestic unlisted shares will be converted into H Shares, and the Company will apply for the listing of, and permission to deal in, such H Shares on the Main Board of the Stock Exchange (the "**Conversion and Listing**"). Pursuant to the articles of association of the Company, no further shareholders' meeting is required to be convened to approve the Conversion and Listing.

As of the date of this announcement, the Company has not completed the filing procedures with the CSRC, and the details of the implementation plan of the Conversion and Listing have not been finalised. The Conversion and Listing remain subject to the performance of other relevant procedures required by the CSRC, the Stock Exchange and other relevant domestic and overseas regulatory authorities. The Company will make further announcement(s) on the progress of the Conversion and Listing in compliance with the Listing Rules and/or the Inside Information Provisions as and when appropriate.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Guangzhou Innogen Pharmaceutical Group Co., Ltd.
Dr. WANG QINGHUA
Chairman of the Board

Shanghai, the People's Republic of China, 17 March 2026

As at the date of this announcement, the Board comprises Dr. WANG QINGHUA, Ms. Jiang Fan, Ms. Xu Wenjie and Mr. Huang Bing as executive Directors; Mr. HO KYUNG SHIK and Mr. Heng Lei as non-executive Directors; and Mr. Tao Wuping, Dr. Song Ruilin and Mr. Chan Heung Wing Anthony as independent non-executive Directors.